Home/Filings/4/0000950170-25-033597
4//SEC Filing

Sabag Mark 4

Accession 0000950170-25-033597

CIK 0000818686other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 4:16 PM ET

Size

7.4 KB

Accession

0000950170-25-033597

Insider Transaction Report

Form 4
Period: 2025-03-03
Sabag Mark
See "Remarks"
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2025-03-03+24,900229,864 total
  • Exercise/Conversion

    Restricted Share Units

    2025-03-0324,90049,801 total
    Ordinary Shares (24,900 underlying)
Footnotes (3)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]Restricted share units were granted on March 3, 2023, with 24,900 vested on each of March 3, 2024 and March 3, 2025, 24,900 vesting on March 3, 2026, and 24,901 vesting on March 3, 2027.

Documents

1 file

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001721442

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:16 PM ET
Size
7.4 KB